{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"433"},{"groupId":"OG001","value":"390"},{"groupId":"OG002","value":"333"},{"groupId":"OG003","value":"294"},{"groupId":"OG004","value":"329"}]}],"title":"Experienced an adverse event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"35"},{"groupId":"OG004","value":"74"}]}],"title":"Experienced a serious adverse event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"32"}]}],"title":"Experienced AE leading to withdrawal"}],"denoms":[{"counts":[{"groupId":"OG000","value":"538"},{"groupId":"OG001","value":"509"},{"groupId":"OG002","value":"463"},{"groupId":"OG003","value":"434"},{"groupId":"OG004","value":"414"}],"units":"Participants"}],"description":"The number of participants experiencing at least one adverse event (AE) is recorded for each 12-month time period, with multiple occurrences in a single individual counted. Because months were calculated as 28 days, the periods actually equate to 48 weeks.","groups":[{"description":"Participants with scores during Months 0-12, which equates to baseline through Week 48.","id":"OG000","title":"Months 0 - 12"},{"description":"Participants with scores during Months 13 - 24, which equates to Weeks 49-96.","id":"OG001","title":"Months 13 - 24"},{"description":"Participants with scores during Months 25 - 36, which equates to Weeks 97-144.","id":"OG002","title":"Months 25 - 36"},{"description":"Participants with scores during Months 37 - 48, which equates to Weeks 145-192.","id":"OG003","title":"Months 37 - 48"},{"description":"Participants with scores during Months greater than 48, which equates to Weeks 193-264.","id":"OG004","title":"Months Greater Than 48"}],"paramType":"NUMBER","populationDescription":"All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.","reportingStatus":"POSTED","timeFrame":"through 264 Weeks","title":"Adverse Event (AE) Summary Over Time","type":"PRIMARY","unitOfMeasure":"Participants"}